BioSpace News Archive

Safety cohort in the investigator sponsored multiple myeloma study, receiving both carfilzomib and Opdivo®, is now complete and pelareorep will be added to the combination in the next cohort in the coming weeks

SOM Biotech, a clinical-stage drug discovery and development company focused on orphan diseases, closes a remarkable year, achieving relevant advances in its drug development pipeline leveraging on its proprietary AI-based drug discovery technology SOMAI-PRO.

Hensel Phelps, SmithGroup and AVRP Studios Complete $244 Million Expansion That Adds Private Patient Rooms, State-of-the-Art Operating Rooms, and More to South Bay’s Largest Hospital

The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials [13-January-2020] REHOVOT, Israel , Jan. 14, 2020 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), anno

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, provided a corporate update and outlined its key corporate and R&D priorities for 2020.

Lokavant has entered into multi-year enterprise license agreement with Parexel

Bausch Health Companies Inc. has published a brief company update presentation designed to complement remarks that will be provided by management during a fireside chat at 1:30 p.m. PT during the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

DiNAQOR AG announced a research collaboration and exclusive license agreement with UCL to develop novel gene therapies for the treatment of monogenic cardiomyopathies, diseases of the heart muscle that can lead to heart failure in children and adults.

Exceeds 2019 metrics with 166 REMS-certified facilities and 148 formulary approvals through December 31, greater than the year-end goals of 125 for each

Medicenna Therapeutics Corp. announced that it has completed a retrospective study on subjects with recurrent Glioblastoma who matched eligibility requirements of subjects enrolled in the MDNA55-05 clinical trial.